IP Library Granted Patent US 12,633,406
Granted Patent B2
US 12,633,406 · App. 18/033,327 · Granted May 19, 2026

System and method for adaptive user experience cycle profiling under anomalous environmental respiratory conditions

Inventor: Patrick Assouad (Ottawa, CA)
Assignee: SPECTRONIX INC.
G16H40/63B63C11/02A61B5/14542B63C2011/021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,633,406
App. No.
18/033,327
Granted
May 19, 2026
Kind
B2
Abstract

Described are various embodiments of a system and method for adaptive user experience cycle profiling under anomalous environmental respiratory conditions, such as in hyperbaric or hypobaric environments. In one embodiment, the system comprises an environmental sensor operable to monitor a respiratory environment parameter representative of the anomalous environmental respiratory condition that defines the experience cycle; and a physiological sensor operable to concurrently monitor a physiological parameter representative of the user's cumulative physiological response to the anomalous environmental respiratory condition over time during the experience cycle.

Claims (41)

1 . An system for monitoring a user exposed to an anomalous environmental respiratory condition during an anomalous respiratory environment experience cycle having a maximum exposure risk defined therefor, the system comprising:

an environmental sensor operable to monitor a respiratory environment parameter representative of the anomalous environmental respiratory condition that defines the experience cycle;

a physiological sensor operable to concurrently monitor a physiological parameter representative of the user's cumulative physiological response to the anomalous environmental respiratory condition over time during the experience cycle; and

a digital data processor having stored in association therewith operable to monitor said physiological parameter against a user-agnostic exposure risk profile designated to avoid exceeding the maximum exposure risk for a generic user exposed to the experience cycle based on an anticipated condition of the generic user as a function of a cumulative exposure during the experience cycle, wherein said digital data processor is operable to monitor said physiological parameter against said user-agnostic exposure risk profile and identify therefrom an adapted user-specific exposure risk profile that deviates from said user-agnostic exposure risk profile to automatically output an adaptive exposure risk indicator in accordance with said adapted user-specific exposure risk profile that adaptively guides customization of the experience cycle while adhering to the maximum exposure risk;

wherein said digital data processor automatically evaluates a user's current condition based on said physiological parameter;

upon said current condition being automatically evaluated as substantially worse than the anticipated condition for a current cumulative exposure, automatically adapts said user-specific exposure risk profile to reflect an increased user-specific cumulative exposure risk for the user and thereby reduce an overall acceptable cumulative exposure setting associated with the experience cycle;

upon said current condition being automatically evaluated as substantially better than the anticipated condition for a current cumulative exposure, automatically adapts said user-specific exposure risk profile to reflect a reduced user-specific cumulative exposure risk for the user and thereby increase an overall acceptable cumulative exposure setting associated with the experience cycle.

2 . The system of claim 1 , wherein said digital data processor is operable to adaptively compute said user-agnostic exposure risk profile over time based on said respiratory environment parameter.

3 . The system of claim 1 , wherein said adaptive exposure risk indicator comprises an adaptive maximum experience duration value, wherein said adaptive maximum experience duration value is set for a given or a maximum depth.

4 . The system of claim 1 , wherein the experience comprises a hypobaric experience, and wherein said respiratory environment parameter comprises a current high altitude value and an exposure duration for said current high altitude.

5 . The system of claim 1 , wherein the experience comprises a hyperbaric experience, and wherein said respiratory environment parameter comprises a current depth and an exposure duration for said depth.

6 . The system of claim 1 , wherein said physiological parameter comprises at least one of a blood oxygen value or a tissue oxygen value.

7 . The system of claim 1 , wherein said physiological parameter comprises an absolute concentration of at least one of deoxyhemoglobin, oxyhemoglobin or dissolved oxygen.

8 . The system of claim 1 , wherein said physiological parameter comprises at least three of carbon monoxide, melanin, cytochrome oxidase, oxyhemoglobin, or deoxyhemoglobin.

9 . The system of claim 1 , wherein said physiological parameter comprises at least one of a blood inert gas value or a tissue inert gas value.

10 . The system of claim 1 , wherein said digital data processor is further operable to automatically evaluate said adapted user-specific exposure risk profile over multiple exposure cycles to predictively output subsequent adapted user-specific exposure risk profiles, wherein each said adapted user-specific exposure risk profile is digitally evaluated to update a user-specific physiological response model representative of the user's anticipated response to said multiple exposure cycles, and wherein said user-agnostic exposure risk profile is automatically adapted for a subsequent exposure cycle as a function of said user-specific physiological response model.

11 . The system of claim 1 , wherein said physiological sensor comprise an infrared or near-infrared probe, wherein said physiological sensor comprises a broad spectrum oximeter.

12 . A computer-implemented method, implemented by one or more digital processors, for monitoring a user exposed to an anomalous environmental respiratory condition during an anomalous respiratory environment experience cycle having a maximum exposure risk defined therefor, the method comprising:

receiving as input, via an environmental sensor, a respiratory environment parameter representative of the anomalous environmental respiratory condition that defines the experience cycle;

concurrently receiving as input, via a physiological sensor, a physiological parameter representative of the user's cumulative physiological response to the anomalous environmental respiratory condition over time during the experience cycle; and

digitally monitoring said physiological parameter against a stored user-agnostic exposure risk profile designated to avoid exceeding the maximum exposure risk for a generic user exposed to the experience cycle based on an anticipated condition of the generic user as a function of a cumulative exposure during the experience cycle, and identifying therefrom an adapted user-specific exposure risk profile that deviates from said user-agnostic exposure risk profile; and

automatically outputting an adaptive exposure risk indicator in accordance with said adapted user-specific exposure risk profile that adaptively guides customization of the experience cycle while adhering to the maximum exposure risk, wherein said user-agnostic exposure risk profile is adaptively computed over time based on said respiratory environment parameter;

wherein said monitoring and identifying comprises automatically evaluating a user's current condition based on said physiological parameter;

upon said current condition being automatically evaluated as substantially worse than an anticipated condition for a current cumulative exposure, automatically adapting said user-specific exposure risk profile to reflect an increased user-specific cumulative exposure risk for the user and thereby reduce an overall acceptable cumulative exposure setting associated with the experience cycle; and

upon said current condition being automatically evaluated as substantially better than an anticipated condition for a current cumulative exposure, automatically adapting said user-specific exposure risk profile to reflect a reduced user-specific cumulative exposure risk for the user and thereby increase an overall acceptable cumulative exposure setting associated with the experience cycle.

13 . The computer-implemented method of claim 12 , wherein said adaptive exposure risk indicator comprises an adaptive maximum experience duration value, wherein said adaptive maximum experience duration value is set for a given or a maximum depth.

14 . The computer-implemented method of claim 12 , wherein the experience comprises a hypobaric experience, and wherein said respiratory environment parameter comprises a current high altitude value and an exposure duration for said current high altitude.

15 . The computer-implemented method of claim 12 , wherein the experience comprises a hyperbaric experience, and wherein said respiratory environment parameter comprises a current depth and an exposure duration for said depth.

16 . The computer-implemented method of claim 12 , further comprising automatically evaluating said adapted user-specific exposure risk profile over multiple exposure cycles to predictively output subsequent adapted user-specific exposure risk profiles, wherein each said adapted user-specific exposure risk profile is digitally evaluated to update a user-specific physiological response model representative of the user's anticipated response to said multiple exposure cycles, and wherein said user-agnostic exposure risk profile is automatically adapted for a subsequent exposure cycle as a function of said user-specific physiological response model.

17 . A non-transitory computer-readable medium comprising digital instructions for implementation by one or more digital processors for monitoring a user exposed to an anomalous environmental respiratory condition during an anomalous respiratory environment experience cycle having a maximum exposure risk defined therefor, by:

accessing a respiratory environment parameter representative of the anomalous environmental respiratory condition that defines the experience cycle;

concurrently accessing a physiological parameter representative of the user's cumulative physiological response to the anomalous environmental respiratory condition over time during the experience cycle; and

digitally monitoring said physiological parameter against a stored user-agnostic exposure risk profile designated to avoid exceeding the maximum exposure risk for a generic user exposed to the experience cycle based on an anticipated condition of the generic user as a function of a cumulative exposure during the experience cycle, and identifying therefrom an adapted user-specific exposure risk profile that deviates from said user-agnostic exposure risk profile; and

automatically outputting an adaptive exposure risk indicator in accordance with said adapted user-specific exposure risk profile that adaptively guides customization of the experience cycle while adhering to the maximum exposure risk, wherein said user-agnostic exposure risk profile is adaptively computed over time based on said respiratory environment parameter;

wherein said monitoring and identifying comprises automatically evaluating a user's current condition based on said physiological parameter;

upon said current condition being automatically evaluated as substantially worse than an anticipated condition for a current cumulative exposure, automatically adapting said user-specific exposure risk profile to reflect an increased user-specific cumulative exposure risk for the user and thereby reduce an overall acceptable cumulative exposure setting associated with the experience cycle; and

upon said current condition being automatically evaluated as substantially better than an anticipated condition for a current cumulative exposure, automatically adapting said user-specific exposure risk profile to reflect a reduced user-specific cumulative exposure risk for the user and thereby increase an overall acceptable cumulative exposure setting associated with the experience cycle.

18 . The non-transitory computer-readable medium of claim 17 , wherein said adaptive exposure risk indicator comprises an adaptive maximum experience duration value, wherein said adaptive maximum experience duration value is set for a given or a maximum depth.

19 . The non-transitory computer-readable medium of claim 17 , wherein the experience comprises a hypobaric experience, and wherein said respiratory environment parameter comprises a current high altitude value and an exposure duration for said current high altitude.

20 . The non-transitory computer-readable medium of claim 17 , wherein the experience comprises a hyperbaric experience, and wherein said respiratory environment parameter comprises a current depth and an exposure duration for said depth.

21 . The non-transitory computer-readable medium of claim 17 , further comprising automatically evaluating said adapted user-specific exposure risk profile over multiple exposure cycles to predictively output subsequent adapted user-specific exposure risk profiles, wherein each said adapted user-specific exposure risk profile is digitally evaluated to update a user-specific physiological response model representative of the user's anticipated response to said multiple exposure cycles, and wherein said user-agnostic exposure risk profile is automatically adapted for a subsequent exposure cycle as a function of said user-specific physiological response model.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2023
From: ASSOUAD, PATRICK
To: SPECTRONIX INC.
Reel/Frame 064341/0265 →
Continuity (3)
Provisional Application 63125367 · Dec 14, 2020
Provisional Application 63105223 · Oct 24, 2020
Related Publication 20230395249A1 · Dec 7, 2023
References Cited (105)
US 4775116A · Klein · 1988 [cited by applicant]
US 5315995A · Rivers · 1994 [cited by applicant]
US 5355882A · Ukawa et al. · 1994 [cited by applicant]
US 5372134A · Richardson · 1994 [cited by applicant]
US 5388575A · Taube · 1995 [cited by applicant]
US 5457284A · Ferguson · 1995 [cited by applicant]
US 6671529B2 · Claure et al. · 2003 [cited by applicant]
US 7127278B2 · Melker et al. · 2006 [cited by applicant]
US 7190999B2 · Geheb et al. · 2007 [cited by applicant]
US 8712493B2 · Ukawa · 2014 [cited by applicant]
US 9014772B2 · Yamaguchi et al. · 2015 [cited by applicant]
US 9131881B2 · Diab et al. · 2015 [cited by applicant]
US 9579060B1 · Lisy et al. · 2017 [cited by applicant]
US 9775546B2 · Diab et al. · 2017 [cited by applicant]
US 10531819B2 · Diab et al. · 2020 [cited by applicant]
US 10660551B2 · Koyama et al. · 2020 [cited by applicant]
US 10674948B2 · Diab et al. · 2020 [cited by applicant]
US 11071480B2 · Diab et al. · 2021 [cited by applicant]
US 12064247B2 · Everman · 2024 [cited by examiner]
US 20020019587A1 · Cheng et al. · 2002 [cited by applicant]
US 20030050541A1 · Wuori · 2003 [cited by applicant]
US 20040267325A1 · Geheb et al. · 2004 [cited by applicant]
US 20050070778A1 · Lackey et al. · 2005 [cited by applicant]
US 20050228246A1 · Lee et al. · 2005 [cited by applicant]
US 20060173258A1 · Kobayashi et al. · 2006 [cited by applicant]
US 20070213964A1 · Goldman · 2007 [cited by applicant]
US 20080139908A1 · Kurth · 2008 [cited by applicant]
US 20080171311A1 · Centen et al. · 2008 [cited by applicant]
US 20080200775A1 · Lynn · 2008 [cited by applicant]
US 20080262327A1 · Kato · 2008 [cited by applicant]
US 20080269589A1 · Thijs et al. · 2008 [cited by applicant]
US 20080306337A1 · Livingston et al. · 2008 [cited by applicant]
US 20100076319A1 · Mannheimer et al. · 2010 [cited by applicant]
US 20110218409A1 · Kugler et al. · 2011 [cited by applicant]
US 20110245711A1 · Katra et al. · 2011 [cited by applicant]
US 20120065486A1 · Imran · 2012 [cited by applicant]
US 20130281803A1 · Scheele et al. · 2013 [cited by applicant]
US 20140012144A1 · Crone · 2014 [cited by applicant]
US 20140100788A1 · Heikkinen et al. · 2014 [cited by applicant]
US 20150254414A1 · Patel · 2015 [cited by applicant]
US 20170071550A1 · Newberry · 2017 [cited by applicant]
US 20170112422A1 · Hatch · 2017 [cited by applicant]
US 20170119254A1 · Ando et al. · 2017 [cited by applicant]
US 20170224220A1 · Tunnell et al. · 2017 [cited by applicant]
US 20170325784A1 · Friedrich et al. · 2017 [cited by applicant]
US 20180001980A1 · Hulbert · 2018 [cited by applicant]
US 20180207058A1 · Xu et al. · 2018 [cited by applicant]
US 20180310822A1 · Indorf et al. · 2018 [cited by applicant]
US 20190290194A1 · Umekawa et al. · 2019 [cited by applicant]
US 20200310098A1 · Ince et al. · 2020 [cited by applicant]
CA 3077122 · 2021 [cited by applicant]
CA 3115419 · 2021 [cited by applicant]
CN 1245407 · 2000 [cited by applicant]
CN 1326328 · 2001 [cited by applicant]
CN 103203013 · 2013 [cited by applicant]
EP 1304955 · 2003 [cited by applicant]
EP 2075189 · 2009 [cited by applicant]
JP H05124592 · 1993 [cited by applicant]
JP 1993207993 · 2000 [cited by applicant]
JP 3116252 · 2000 [cited by applicant]
JP 2008534083 · 2008 [cited by applicant]
JP 2009501041 · 2009 [cited by applicant]
JP 2018536516 · 2018 [cited by applicant]
JP 2019502418 · 2019 [cited by applicant]
WO 2007080303 · 2007 [cited by applicant]
WO 2008013506 · 2008 [cited by applicant]
WO 2009022926 · 2009 [cited by applicant]
WO 2010129528 · 2010 [cited by applicant]
WO 2013165887 · 2013 [cited by applicant]
WO 2017078637 · 2017 [cited by applicant]
WO 2019081547 · 2019 [cited by applicant]
WO 2019213783 · 2019 [cited by applicant]
WO 2022082322 · 2022 [cited by applicant]
WO 2022082323 · 2022 [cited by applicant]
International Search Report and Written Opinion issued in Application No. PCT/CA2021/051499, 9 pages, dated Jan. 27, 2022. [cited by applicant]
U.S. Appl. No. 17/046,704, filed May 10, 2019, Patrick Assouad. [cited by applicant]
U.S. Appl. No. 63/105,223, filed Oct. 24, 2020, Patrick Assouad. [cited by applicant]
U.S. Appl. No. 63/125,367, filed Dec. 14, 2020, Patrick Assouad. [cited by applicant]
Bein et al. Monitoring of cerebral oxygenation with near infrared spectroscopy and tissue oxygen partial pressure during cardiopulmonary resuscitation in pigs. European Journal of Anaesthesiology 2006; 23: 501-509. [cited by applicant]
Callaway. Cerebral Oximetry and Cardiopulmonary Resuscitation. Journal of the American Heart Association. Jul. 28, 2021. pp. 1-2. [cited by applicant]
Chien et al. Cerebral Oxygenation During Hypoxia and Resuscitation by Using Near-infrared Spectroscopy in Newborn Piglets. ChinMedAssoc • Feb. 2007 • vol. 70 • No. 2. pp 47-55. [cited by applicant]
Genbrugge et al. Regional Cerebral Oximetry During Cardiopulmonary Resuscitation: Useful Or Useless? The Journal of Emergency Medicine, vol. 50, No. 1, pp. 198-207, 2016. [cited by applicant]
Green et al. Cerebral oximetry and its role in adult cardiac, non-cardiac surgeryand resuscitation from cardiac arrest. Anaesthesia 2017, 72 (Suppl. 1), 48-57. [cited by applicant]
Hanning CD, Alexander-Williams JM. Pulse oximetry: a practical review. BMJ. 1995;311(7001):367-370. doi:10.1136/bmj.311.7001.367. [cited by applicant]
Hirose et al. Pre-hospital portable monitoring of cerebral regional oxygen saturation (rSO2) in seven patients with out-of-hospital cardiac arrest. BMC Res Notes (2016) 9:428 pp. 1-5. [cited by applicant]
Ibrahim et al. Cerebral Oximetry as a Real-Time Monitoring Tool to Assess Quality ofln-Hospital Cardiopulmonary Resuscitation and Post Cardiac Arrest Care. Journal of the American Heart Association. Jul. 28, 2021. pp. 1… [cited by applicant]
Jones, et al., Underwater near-infrared spectroscopy measurements of muscle oxygenation: laboratory validation and preliminary observations in swimmers and triathletes, Journal of Biomedical Optics 19(12), Dec. 2014. [cited by applicant]
Larsson A., Uusijärvi J., Eksborg S., “Tissue oxygenation measured with near-infrared spectroscopy during normobaric and hyperbaric oxygen breathing in healthy subjects”, European Journal of Applied Physiology, 2010, pp… [cited by applicant]
Litscher et al., Transcranial Cerebral Oximetry in the Hyperbaric Environment, Department of Anesthesiology and Intensive Care Medicine, Biomed, Technik, 42 (1997) p. 38. [cited by applicant]
Litscher G., Schwarz G., Ratzenhofer-Komenda B., Kovacs H., Gabor S., Stolle-Jüttner F. M., “Transcranial Cerebral Oximetry in the Hyperbaric Environment”, Biomedizinische Technik, 1997, pp. 38-41, vol. 42. [cited by applicant]
Masimo, Oxygen Reserve Index (ORi), Whitepaper, 2017. [cited by applicant]
McLeod et al., Measuring Cerebral Oxygenation During Normobaric Hyperoxia: A Comparison of Tissue Microprobes, Near-Infrared Spectroscopy, and Jugular Venous Oximetry in Head Injury, Departments of *Neuroanaesthesia and… [cited by applicant]
Meter—Hyperbaric Oxygen in Resuscitation. Springer International Publishing AG 2017K.K. Jain, Textbook of Hyperbaric Medicine. 551-566. [cited by applicant]
Olafsdottir OB, Eliasdottir TS, Kristjansdottir JV, Hardarson SH, Stefansson E (2015) “Retinal Vessel Oxygen Saturation during 100% Oxygen Breathing in Healthy Individuals.” PLoS ONE 10(6): e0128780. doi:10.1371/journal… [cited by applicant]
Parnia. Cerebral oximetry—The holy grail of non-invasive cerebral perfusion monitoring in cardiac arrest or just a false dawn? Editorial / Resuscitation 83 (2012) 11-12. Oct. 27, 2011. [cited by applicant]
Patterson, et al., Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties, Applied Optics, vol. 28, No. 12, Jun. 15, 1989 (p. 2331-2336). [cited by applicant]
Price et al. Response to Use of Cerebral Oximetry During Cardiac Arrest. Online Letters to the Editor. Mar. 2017, vol. 45, No. 3. e334-e335. [cited by applicant]
Putzer et al. Monitoring of brain oxygenation during hypothermic CPR—A prospective porcine study. Resuscitation 104 (2016) pp. 1-5. [cited by applicant]
Sanfilippoa et al. “Cerebral oximetry and return of spontaneous circulation after cardiac arrest: A systematic review and meta-analysis”. Elsevier. Resuscitation 94 (2015) 67-72. [cited by applicant]
Suzuki, et al., A Tissue Oxygenation Monitor using NIR Spatially Resolved Spectroscopy, Proceedings of Optical Tomography and Spectroscopy of Tissue III, San Jose, California, SPIE vol. 2597, Jan. 1999. [cited by applicant]
Taccone. Cerebral oximetry during extracorporeal cardiopulmonary resuscitation. Critical Care 2013, 17:409 pp. 1-2. [cited by applicant]
Tajima et al. “Portable system for monitoring of regional cerebral oxygen saturation during prehospital cardiopulmonary resuscitation: a pilot study”. Brief Communication. Acute Medicine & Surgery 2015; 2: 48-52. [cited by applicant]
Takegawa et al. Near-Infrared Spectroscopy Assessments of Regional CerebralOxygen Saturation for the Prediction of Clinical Outcomes in Patients WithCardiac Arrest: A Review of Clinical Impact, Evolution, and Future Dir… [cited by applicant]
Parnia et al., “Cerebral Oximetry During Cardiac Arrest: A Multicenter Study of Neurological Outcomes and Survival” pp. 1-27. [cited by applicant]
China National Intellectual Property Administration: First Office Action issued for Application No. 202180087216.4, 28 pages, dated Dec. 3, 2025. [cited by applicant]